Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Adrenocortical adenoma

Protein kinase cAMP-dependent catalytic-a (PRKACA)

DNA sequencing of patient samples and in vitro studies suggest inhibiting PRKACA could treat adrenocortical carcinoma. DNA sequencing of patient tumors and matched normal tissues identified mutations in about 50% of patients with corticotrophin-dependent Cushing syndrome, which is caused by excessive cortisol production by adrenocortical adenomas. In vitro, disease-associated mutations increased PRKACA's kinase activity compared with wild-type PRKACA. Next steps could include identifying selective PRKACA inhibitors.

SciBX 7(25); doi:10.1038/scibx.2014.728
Published online June 26, 2014

Patents pending on biomarkers and therapeutics for corticotrophin-dependent Cushing syndrome; licensing status undisclosed

Sato, Y. et al Science; published online May 23, 2014;
doi:10.1126/science.1252328
Contact: Seishi Ogawa, Kyoto University, Kyoto, Japan
e-mail:

sogawa-tky@umin.ac.jp
Contact: Yukio Homma, same affiliation as above
e-mail:

homma-uro@umin.ac.jp